Business Wire

 New Conviva Data Reveals Streaming in Europe Holding onto Pandemic Gains with 19% Year-over-year Growth

9.9.2021 05:00:00 EEST | Business Wire | Press release

Share

Conviva, the intelligence cloud for streaming media, released its State of Streaming: Europe report for Q2 2021 today, revealing streaming growth in Europe held onto pandemic gains, growing 19% year over year and outpacing global streaming growth (13%) for the same time period. Western Europe led Europe’s streaming growth with 32% year over year gains, followed by northern Europe at 23%. Viewership in southern and eastern Europe was down 1% year over year.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210908006109/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Conviva's State of Streaming Europe - Q2 2021 (Graphic: Business Wire)

"European viewers continue to embrace streaming at a rapid rate, mirroring what is happening in every corner of the world and even outpacing some regions,” said Keith Zubchevich, CEO, Conviva. “As more and more people flock to streaming, the onus is on publishers in Europe and across the globe to provide a high-quality viewing experience for consumers, but they cannot do so without consistent, accurate, real-time measurement which is also critical to grow and monetize their streaming business in a highly competitive environment."

Connected TV Devices Continue to Dominate

Connected TV devices dominated Europe as the streaming device of choice maintaining a 32% share of all viewing time. Desktop and tablets saw no change from Q2 2020, still at 14% and 11% share, respectively. Mobile phones gained 1% and smart TVs gained 2%, while gaming consoles dropped in share of viewing time, down 3%. Among big screen viewing in Europe, Samsung TV led with 19% market share followed by Chromecast at 12% and Amazon Fire TV at 11%. This is in contrast to global numbers where Roku held a solid leadership position with 31%.

Europe’s Football Leagues Celebrate Resurgence on Social Media

Q2 2021 was the first quarter since the beginning of 2020 where European sports leagues showed an increase year over year in social posts, videos and engagements. Even as the UEFA Euro 2020 tournament took precedence over league play, European leagues, including Bundesliga, La Liga, Premier League and Serie A showed strong quarter-over-quarter growth, up 68% in social engagements despite only increasing videos by 2% and posts by 20%.

Streaming Quality Improves

The report also found several facets of streaming quality in Europe improved in Q2 2021, with video start failures down 12% for the continent year over year, led by eastern Europe with a 21% improvement in video start failures. Picture quality also improved, with bitrate up 43% in Europe overall led by southern Europe with a 51% increase. Quality of streaming ads improved significantly in Q2 2021, with only 16% of ads around the world representing missed opportunities (ads that went unfilled or failed to play as expected), down from 37% the previous quarter. While global ad attempts dropped 8% from Q1 to Q2 2021, more attempts were successful, resulting in a 4% increase overall in ad impressions. What’s more, in Q2 2021, viewers spent 31% less time waiting for ads to play and ad duration decreased 3% to 27 seconds.

The full report can be downloaded here.

Methodology

Data for Conviva’s State of Streaming report was primarily collected from Conviva’s proprietary sensor technology currently embedded in 3.3 billion streaming video applications, measuring in excess of 500 million unique viewers watching 180 billion streams per year with nearly 2 trillion real-time transactions per day across more than 180 countries. Year-over-year comparisons were normalized at the customer level for accurate representations of industry growth. The social media data consists of data from over 2000 accounts, over 5 million posts, 12.5 billion video views and over 35 billion engagements across Facebook, Instagram, Twitter and YouTube.

About Conviva

Conviva is the intelligence cloud for streaming media. Powered by our patented Stream Sensor™ and Stream ID™, our real-time platform enables marketers, advertisers, tech ops, engineering and customer care teams to build, engage and monetize their audiences. Conviva is dedicated to supporting brands like CCTV, DAZN, Disney+, Hulu, Paramount+, Peacock, Sky, Sling TV, TED and WarnerMedia as they unlock the incredible opportunity in streaming media. Today our platform processes nearly 2 trillion streaming data events daily, supporting more than 500 million unique viewers watching 180 billion streams per year across 3.3 billion applications streaming on devices. Conviva ensures digital businesses of all sizes can stream better—every stream, every screen, every second. To learn more, visit www.conviva.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Paula Winkel - pr@conviva.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye